Isoprostenes as indicators of oxidative stress in schizophrenia

World Journal of Biological Psychiatry

Volumn 10, Issue 1, 2009, Pages 27-33

  Dietrich Muszalska, Anna ^a   Olas, Beata ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

Isoprostanes; Oxidative stress; Schizophrenic disorders; TBARS; Thromboxane B2

Indexed keywords

11 OXOTHROMBOXANE B2; ARACHIDONIC ACID; CLOZAPINE; FREE RADICAL; ISOPROSTANE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THROMBOXANE B2; UNSATURATED FATTY ACID;

ADULT; ARTICLE; CATALYSIS; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DISEASE DURATION; DYSKINESIA; ENZYME ACTIVITY; ENZYME METABOLISM; HUMAN; IMMUNOASSAY; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; NON INVASIVE MEASUREMENT; OXIDATIVE STRESS; PROGNOSIS; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINARY EXCRETION;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; DINOPROST; FEMALE; FREE RADICALS; HUMANS; ISOPROSTANES; LIPID PEROXIDATION; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; SCHIZOPHRENIA, PARANOID; THIOBARBITURIC ACID REACTIVE SUBSTANCES; THROMBOXANE B2;

EID: 61649102890     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701361263     Document Type: Article

References (49)

1. Akyol, O., Herken, H. Zu, E. et al. (2002) The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuro-Psychopharmacol Biol Psychiatr, 26, pp. 995-1005.
2. Basu, S. (2004) Isoprostanes: Novel bioactive products of lipid peroxidation. Free Radic Res, 38, pp. 105-122.
3. Cracowski, JL, Devillier, P., Durand, T., Stanke-Labesque, F. and Bessard, G. (2001) Vascular biology of the isoprostanes. J Vasc Res, 38, pp. 93-103.
4. Cracowski, JL, Durand, T. and Bessard, G. (2002) Isoprostanes as a biomarker of lipid peroxidation in humans: Physiology, pharmacology and clinical implications. Trends Pharmacol Sci, 23, pp. 1-4.
5. Davi, G., Falco, A. and Patrono, C. (2004) Determinations of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids, 128, pp. 149-163.
6. Deminisch, L., Gerbaldo, H., Gebhart, P., Georgi, K. and Bochnik, HJ (1987) Incorporation of 14C-arachidonic acid into platelet phospholipids of untreated patients with schizophrenic form or schizophrenic disorders. Psychiatr Res, 22, pp. 275-282.
7. Dietrich-Muszalska, A., Rabe-Jablonska, J. and Zgirski, A. (2004) Wpływ dzialania olanzapiny (Zolafren) na peroksydacje lipidow w ludzkich płytkach krwi i osoczu w układzie in vitro. Psychiatria i Psychologia Kliniczna, 4, pp. 13-19.
8. Dietrich-Muszalska, A., Olas, B. and Rabe-Jablonska, J. (2005) Oxidative stress in blood platelets from schizophrenic patients. Platelets, 16, pp. 386-391.
9. Fendri, C., Mechri, A., Khiari, G., Othman, A., Kerkeni, A. and Gaha, L. (2006) Oxidative stress involvement in schizophrenia pathophysiology: A review. Encephale, 32, pp. 244-252.
10. Fenton, WS, Hibbeln, J. and Knable, M. (2000) Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatr, 47, pp. 8-21.
11. Funk, CD (2001) Platelet eicosanoids. Hemostasis and thrombosis. Basic principles and clinical practice. Chapter 30, pp. 533-539. Lippincott Williams & Wilkins, Philadelphia, PA
12. Gao, L., Yin, H., Milne, GL, Porter, NA and Morrow, JD (2006) Formation of f-ring isoprostane-like compounds (F3-isoprostanes) in vivo from eicosapentaenoic acid.
13. Glen, AIM, Glen, EMT Horrobin, DF et al. (1994) A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophr Res, 12, pp. 53-61.
14. Greco, A., Minghetti, L. and Levi, G. (2000) Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res, 25, pp. 1357-1364.
15. Horrobin, DF (1996) Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukotr Essent Fatty Acids, 55, pp. 3-7.
16. Horrobin, DF (1977) Schizophrenia as a prostaglandin deficiency disease. Lancet, 1, pp. 936-937.
17. Horrobin, DF, Manku, MS, Hillman, H., Iain, A. and Glen, M. (1991) Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatr, 30, pp. 795-805.
18. Jeding, I., Evans, PJ Akanmu, D. et al. (1995) Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol, 49, pp. 359-365.
19. Khan, NS and Das, I. (1997) Oxidative stress and superoxide dismutase in schizophrenia. Biochem Soc Trans, 25, p. 418S.
20. Kropp, S., Kern, V. Lange, K. et al. (2005) Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry, 17, pp. 227-231.
21. Lachance, PA, Nakat, Z. and Jeong, WS (2001) Antioxidants: An integrative approach. Nutrition, 17, pp. 835-838.
22. Mahadik, SP, Mukherjee, S., Correnti, E. and Scheffer, R. (1995) Elevated levels of lipid peroxidation products in plasma of drug-naive patients at the onset of psychosis. Schizophr Res, 15, p. 66.
23. Mahadik, SP, Mukherjee, S., Scheffer, RS, Correnti, EE and Mahadik, JS (1998) Elevated plasma lipid peroxidation at the onset of nonaffective psychosis. Biol Psychiatr, 43, pp. 674-570.
24. Mehrabi, MR, Serbecic, N. Ekmekcioglu, C. et al. (2001) The isoprostane 8-epi-PGF2α is a valuable indicator of oxidative injury in human heart valves. Cardiovasc Pathol, 10, pp. 241-245.
25. Milne, GL and Morrow, JD (2006) Isoprostanes and related compounds: update 2006. Antioxidants Redox Signaling, 8, pp. 1379-1384.
26. Morrow, JD (2006) The isoprostanes-unique products of arachidonate peroxidation: Their role as mediators of oxidant stress. Curr Pharm Design, 12, pp. 895-902.
27. Morrow, JD, Hill, KE, Burk, RF, Nammour, TM, Badr, KF and Roberts, LJ (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA, 87, pp. 9383-9387.
28. Oguogho, A., Ferlitsch, A. and Sinzinger, H. (2000) LDL-apheresis decreases plasma levels and urinary extretion of 8-epi-PGF2α. Prostaglandins Leukotr Essent Fatty Acids, 62, pp. 209-216.
29. Peet, M., Laugharne, J., Rangarajan, N. and Reynolds, GP (1993) Tardive dyskinesia, lipid peorxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychophamacol, 8, pp. 151-153.
30. Pratico, D., Rokach, J., Lawson, J. and FitzGerald, GA (2004) F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids, 128, pp. 165-171.
31. Reddy, RD and Yao, JK (1999) Membrane protective strategies in schizophrenia: Conceptual and treatment issues. Phospholipid spectrum disorder in psychiatry, pp. 75-88. Marius Press, Lancashire, UK
32. Reilly, MO, Lawson, JA and FitzGerald, GA (1998) Eicosanoids and isoeicosanoids: Indices of cellular function and oxidant stress. J Nutr, 128, pp. 434-438.
33. Robers, LJ II and Morrow, JD (2002) Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation. Cell Mol Life Sci, 59, pp. 808-820.
34. Roberts, LJ II and Reckelhoff, JF (2001) Measurement of F2-isoprostanes unveils profound oxidative tsress in adged rats. Biochem Biohys Res Comm, 287, pp. 254-256.
35. Roberts, LJ II, Montine, TJ Markesbery, WR et al. (1998) Formation of isoprostanes-like compounds (neuroprostanes) in vivo from oxidation of docosahexaenoic acid. J Biol Chem, 273, pp. 13605-13612.
36. Rokach, J., Khanapure, SP, Hwang, SW, Adiyaman, M., Lawson, JA and FitzGerald, GA (1997) The isoprostanes: A perspective. Prostaglandins, 54, pp. 823-851.
37. Rokach, J., Kim, S. Bellone, S. et al. (2004) Total synthesis of isoprostanes: Discovery and quantitation in biological systems. Chem Phys Lipids, 128, pp. 35-56.
38. Ross, BM (2003) Phospholipid and eicosanoid signaling disturbances in schizophrenia. Prostaglandins Leukotr Essent Fatty Acids, 69, pp. 407-412.
39. Rotrosen, J. and Wolkin, A. (1987) Phospholipid and prostaglandin hypotheses of schizophrenia. Psychopharmacology. The third generation of progress, pp. 759-764. Raven Press, New York
40. Sagara, Y. (1998) Induction of reactive oxygen species in neurons by haloperidol. J Neurochem, 71, pp. 1002-1012.
41. Souviget, C., Cracowski, JL, Stanke-Labesque, F. and Bessard, G. (2000) Are isoprostanes a clinical marker for antioxidant drug investigation. Fundam Clin Pharmacol, 14, pp. 1-10.
42. Taber, DF, Morrow, JD and Roberts, JL II (1997) A nomenclature system for the isoprostanes. Prostaglandins, 53, pp. 63-67.
43. Wachowicz, B. (1984) Adenine nucleotides in thrombocytes of birds. Cell Biochem Funct, 2, pp. 167-170.
44. van Kammen, DP, Yao, JK and Goetz, K. (1989) Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann NY Acad Sci, 559, pp. 411-423.
45. Yao, JK, van Yasaei, P. and Kammen, DP (1992) Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins Leukot Essent Fatty Acids, 46, pp. 39-46.
46. Yao, JK, van Kammen, DP and Gurkis, WJ (1994) Correlation of fatty acid abnormalities with clinical measures in schizophrenia. Schizophr Res, 11, p. 124.
47. Yao, JK, Reddy, R., McElhinny, LG and van Elhinny, K. (1998) Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res, 32, pp. 1-8.
48. Yao, JK, Leonard, S. and Reddy, R. (2000) Membrane phospholipids abnormalities in portmorten brains from schizophrenic patients. Schizophr Res, 42, pp. 7-17.
49. Yao, JK, Reddy, RD and Kammen, DP (2001) Oxidative damage and schizophrenia. CNS Drugs, 15, pp. 287-310.